Discontinued — last reported Q4 '25
Year-over-year, this metric declined by 89.7%, from $223.00M to $23.00M. Over 4 years (FY 2021 to FY 2025), Acquisitions shows a downward trend with a -43.2% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $1.89B | $153.00M | $83.00M | $9.00M | $5.00M | $0.00 | $0.00 | $3.00M | $0.00 | $0.00 | $12.00M | $0.00 | $98.00M | $111.00M | $223.00M | $0.00 | $4.00M | $0.00 | $23.00M |
| QoQ Change | — | — | -91.9% | -45.8% | -89.2% | -44.4% | -100.0% | — | — | -100.0% | — | — | -100.0% | — | +13.3% | +100.9% | -100.0% | — | -100.0% | — |
| YoY Change | — | — | — | — | — | -99.7% | -100.0% | -100.0% | -66.7% | -100.0% | — | — | -100.0% | — | — | >999% | — | -95.9% | -100.0% | -89.7% |